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Introduction 
It been amply that the 
hormone release-inhibiting (GH-RIH or 
is also potent inhibitor insulin 
and release. Furthermore, shown recently, 
or a peptide (s) 
produced not in the but, among 
tissues, also the pancreas [I ,2] , most pro- 
bably in the CQ -cells of the pancreatic islets [3,4] . 
It has been suggested by several authors that 
somatostatin - preferably in long-acting form - 
might be of value in the treatment of diseases uch 
as acromegaly, diabetes mellitus, spontaneous 
hyperinsulinism etc. In acromegaly the GH release- 
inhibiting action and in diabetes mellitus the inhibi- 
tion of the release of GH as well as glucagon would 
be of special importance, whereas the insulin inhi- 
biting action would be preferable in hyperinsulinism 
[5]. For this reason analogues to somatostatin have 
been synthetized in an attempt to arrive at sub- 
stances with predominantly one or two of the actions 
of the original somatostatin. This first report shows 
that it is possible by modifying the structure of 
somatostatin to obtain analogues which predomi- 
nantly inhibit insulin release. 
2. Materials and methods 
Sprague-Dawley rats, weighing 200-250 g and 
fasted for 24 h were used for the preparation of the 
perfused isolated pancreas. The animals were anes- 
thetized by intraperitoneal injection of 50 mg/kg of 
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Pentobarbital, and the pancreas was isolated by a 
slight modification of the technique of Loubatikres 
et al. [6]. The pancreas was completely separated 
from adjacent organs, and all vessels were carefully 
ligated.The gland was perfused with a Krebs-Ringer 
bicarbonate solution to which was added 0.8 g/l of 
glucose and 20 g/l of beef albumin. The final solu- 
tion was adjusted to pH 7.4 with 0.1 N HCl: and 
was gassed continuously with a mixture of 95% 
oxygen and 5% carbon dioxide. The perfusate was 
administered into the coeliac artery, and run into 
the prepared pancreas by an open circuit ‘non-recy- 
cling perfusion system’. Total portal effluent was 
collected over 60 sec. Flow rates were kept approxi- 
mately at 2.5 ml/min by making minor changes in 
arterial pressure. The isolated pancreas was always 
equilibrated with perfusion medium for 40 min 
before applying the stimulatory concentration of 
glucose. Somatostatin and somatostatin analogues, 
dissolved in water, were added to the perfusate and 
applied by changing the medium reservoir. 
Larginine monochloride was obtained in a 10% 
aqueous solution (Vitrum AB, Stochkholm) and 
used at adequate dilutions. 
Insulin was determined by a double-antibody 
radioimmunoassay using insulin reagent kits (Radio- 
chemical Centre, Amersham), and a rat insulin stan- 
dard. Glucagon was assayed by the charcoal separation 
radioimmunoassay technique [7], using an antibody 
specific for pancreatic glucagon (30 K, kindly provided 
by Dr Roger Unger, Dallas, Texas). 
The effect of somatostatin on insulin release was 
calculated by comparison of the areas under the 
insulin curves. The initial phase of insulin release was 
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somatostatin 
(linear) 
Table 1 
The sequences of somatostatin and somatostatin analogues 
__-____-_ 
?” PH - 
H-Ala--Gly ~Cys-Lys-Asn-Phe-PheTrp-Lys-Thr-Phe-Thr-SerCys~OH 
analogue WY-18 092 
analogue WY-1 8 166 
SH SH 
H-ICys--Lys--Asn-Phe-Phe-Trp-L,ys-Tnr-Phe-Tnr-Ser-ICys--OH 
P 
__- ______ 
B 
H-Cys--Lys-Phe--Phe -Trp-Lys-Th-Phe-Th-Ser-Cys-OH 
taken as the O-7 min period after the start of the 
infusion, while the second phase comprised the period 
between 7-17 min. 
Growth hormone release was measured in vitro by 
means of monolayer cultures of enzymatically dispers- 
ed pituitary cells [8] and in vivo 15 min after sub- 
cutaneous injection of the peptide and 20 min after 
intraperitoneal injection of Pentobarbital. The soma- 
tostatin analogues were synthetized at Ihe Wyeth 
laboratories, Philadelphia and their structures are 
given in table 1. 
3. Results 
Arginine (5 mg/ml) significantly stimulated insulin 
and glucagon release from the isolated perfused rat 
pancreas. A typical biphasic curve was obtained. 
Somatostatin in a concentration as low as 10 ng/ml, 
when infused 7 min prior to and then during the infu- 
sion of arginine, induced a significant suppression of 
arginine stimulated insulin and glucagon release 
(table 2). This effect was more prominent on the pri- 
mary peak of the insulin and glucagon curve. 
The two analogues significantly inhibited arginine 
enhanced insulin secretion, in this respect being 
approximately as potent as somatostatin. On the other 
hand, analogue WY-18 092 had no effect on glucagon 
secretion, and analogue WY-1 8 166 had only a slight 
and not significant inhibitory effect on glucagon 
release. 
The effect of the somatostatin analogues on growth 
hormone release was tested in vivo and in vitro at the 
Wyeth laboratories. Both analogues were less potent 
inhibitors of growth hormone release than somato- 
statin; the inhibitory activity being about 10% that of 
somatostatin [9]. In vivo data on the effects of WY-18 
166 on growth hormone, glucagon and insulin release 
are reported by Sarantakis et al. [lo] 
[ 1 l] . As shown 
here, arginine-induced release of insulin - as well as 
glucagon - is also inhibited by somatostatin. Further- 
more, the modification of the structure of somato- 
statin resulted in dissociation of the effects on insulin 
and glucagon release. In both analogues dispensing 
with the free-end Ala’-Gly’ of somatostatin was ac- 
companied by decreased or abolished inhibitory acti- 
vity on glucagon but with preserved inhibitory potency 
on insulin release. In addition the deletion of Asn’ 
(WY-18 166) did not seem to influence the activity on 
insulin release. The decrease in the effect of des-Ala’ 
Gly’ AsnS -somatostatin (WY-l 8 166) on glucagon 
release was also demonstrated by Sarantakis et al. [lo] 
on rats in vivo. 
Both analogues still exerted some inhibitory action 
on growth hormone release although this seemed to 
be less pronounced than for somatostatin proper 
[9,10]. These findings indicate that analogues can be 
synthetized which preferentially exhibit only one or 
some of the activities of somatostatin. 
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